Comparing survivals according to different adjuvant treatments in high-risk endometrial carcinoma: an international and propensity score matching study

Background: This study aimed to compare the effectiveness of different adjuvant therapies on oncological outcomes in high-risk endometrial cancer. Methods: A retrospective cohort study analysed data from two tertiary medical centres in Korea and Taiwan (01 January 2000 to31 December 2020). Patients with high-risk endometrial cancer who underwent debulking surgery were eligible for inclusion. Cohort 1 included patients with early stage-to-stage IIIC1disease who achieved complete surgical resection, while Cohort 2 comprised those with residual disease post-surgery or stage IIIC2/IV disease. Propensity score matching was performed. Results: Following propensity score matching, 110 and 70 patients were analysed in Cohorts 1 and 2, respectively. In cohort 1, progression-free survival (PFS) and overall survival (OS) did not differ significantly between patients treated with adjuvant radiotherapy alone and those receiving combined chemotherapy and radiotherapy (PFS hazard ratio (HR) 0.691, 95% confidence interval (CI) 0.360–1.324, p = 0.265; OS HR 0.953, 95% CI 0.375–2.423, p = 0.920). Subgroup analysis suggested a potential improvement in PFS with combination therapy among stage III patients (HR 0.362, 95% CI 0.129–1.015, p = 0.0534), although no OS differences were observed (HR 0.305, 95% CI 0.063–1.471, p = 0.139). In cohort 2, no significant differences were observed in PFS or OS between treatment groups (PFS adjusted HR (aHR) 1.435, 95% CI 0.725–2.841, p = 0.3; OS aHR 1.194, 95%CI 0.505–2.824, p = 0.687). Conclusions: Combined chemotherapy and radiotherapy may improve progression-free outcomes in patients with stage III high-risk endometrial cancer without residual disease post-surgery, compared to radiotherapy alone.

High-risk endometrial cancer; Adjuvant treatment; Propensity score matching

[1] eBioMedicine. Endometrial cancer: improving management among increasing incidence rates. EBioMedicine. 2024; 103: 105159.

[2] Yun BS, Park EH, Ha J, Lee J, Lee KH, Lee TS, et al. Incidence and survival of gynecologic cancer including cervical, uterine, ovarian, vaginal, vulvar cancer and gestational trophoblastic neoplasia in Korea, 1999–2019: Korea Central Cancer Registry. Obstetrics & Gynecology Science. 2023; 66: 545–561.

[3] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023; 73: 17–48.

[4] Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. The Lancet. 2022; 399: 1412–1428.

[5] Rodriguez VE, Tanjasiri SP, Ro A, Hoyt MA, Bristow RE, LeBrón AMW. Trends in endometrial cancer incidence in the United States by race/ethnicity and age of onset from 2000 to 2019. American Journal of Epidemiology. 2025; 194: 103–113.

[6] Saka AH, Giaquinto AN, McCullough LE, Tossas KY, Star J, Jemal A, et al. Cancer statistics for African American and Black people, 2025. CA: A Cancer Journal for Clinicians. 2025; 75: 111–140.

[7] Odagiri T, Watari H, Hosaka M, Mitamura T, Konno Y, Kato T, et al. Multivariate survival analysis of the patients with recurrent endometrial cancer. Journal of Gynecologic Oncology. 2011; 22: 3–8.

[8] Perera J, Hoskin P. Adjuvant therapy for high-risk endometrial carcinoma. Clinical Oncology. 2021; 33: 560–566.

[9] de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology. 2018; 19: 295–309.

[10] Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. The New England Journal of Medicine. 2019; 380: 2317–2326.

[11] Lee SS, Weil CR, Boyd LR, DeCesaris C, Gaffney D, Suneja G. Trends in use of radiation therapy, chemotherapy, and combination chemoradiotherapy in advanced uterine cancer before, during, and after GOG 258. International Journal of Gynecological Cancer. 2023; 33: 1408–1418.

[12] Albuquerque K, Chino J, Klopp A, Kamrava M, Beriwal S. Defining the place of adjuvant chemotherapy and radiation for high-risk endometrial cancer from recent randomized clinical trials: some answers, more questions. International Journal of Radiation Oncology, Biology, Physics. 2018; 102: 473–477.

[13] Chinnadurai A, Breadner D, Baloush Z, Lohmann AE, Black M, D’Souza D, et al. Adjuvant carboplatin and paclitaxel with “sandwich” method radiotherapy for stage III or IV endometrial cancer: long-term follow-up at a single-institution. Journal of Gynecologic Oncology. 2024; 35: e16.

[14] de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. The Lancet Oncology. 2019; 20: 1273–1285.

[15] Barlin JN, Mahar B, Ata A, Cormier B, Michelin D, Salani R, et al. Lunchbox trial: a randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma. Gynecologic Oncology. 2024; 180: 63–69.

[16] Randall ME, Filiaci V, McMeekin DS, von Gruenigen V, Huang H, Yashar CM, et al. Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early-stage endometrial cancer. Journal of Clinical Oncology. 2019; 37: 1810–1818.

[17] Galaal K, Al Moundhri M, Bryant A, Lopes AD, Lawrie TA. Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database of Systematic Reviews. 2014; 2014: CD010681.

[18] Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. British Journal of Cancer. 2006; 95: 266–271.

[19] Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecologic Oncology. 2008; 108: 226–233.

[20] Signorelli M, Lissoni AA, De Ponti E, Grassi T, Ponti S, Fruscio R. Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high-risk endometrial cancer. Journal of Gynecologic Oncology. 2015; 26: 284–292.

[21] Kang OJ, Cho YJ, Lim MC, Lee YJ, Seo SS, Kang S, et al. Docetaxel/cisplatin chemotherapy followed by pelvic radiation therapy in patients with high-risk endometrial cancer after staging surgery: a phase 2 study. International Journal of Radiation Oncology, Biology, Physics. 2025; 121:1229–1236.

[22] Ferrero A, Fuso L, Cipullo I, Danese R, Rossi A, Gribaudo S, et al. The “sandwich” schedule: a well-tolerated adjuvant treatment both in intermediate-high- and high-risk endometrial cancer. Current Oncology. 2022; 29: 9224–9234.

[23] Sahin AB, Ocak B, Abakay CD, Cubukcu E, Deligonul A, Caner B, et al. Chemotherapy plus radiotherapy vs. radiotherapy alone in high-risk endometrioid endometrial carcinoma. European Review for Medical and Pharmacological Sciences. 2022; 26: 8959–8968.

[24] Guo W, Wang T, Lv B, Jiang J, Liu Y, Zhao P. Advances in radiomics research for endometrial cancer: a comprehensive review. Journal of Cancer. 2023; 14: 3523–3531.